Defence Therapeutics Inc. (DTC) - Total Liabilities
Based on the latest financial reports, Defence Therapeutics Inc. (DTC) has total liabilities worth €2.59 Million EUR (≈ $3.03 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Defence Therapeutics Inc. - Total Liabilities Trend (2020–2024)
This chart illustrates how Defence Therapeutics Inc.'s total liabilities have evolved over time, based on quarterly financial data. See Defence Therapeutics Inc. (DTC) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Defence Therapeutics Inc. Competitors by Total Liabilities
The table below lists competitors of Defence Therapeutics Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Woojin I&S Co Ltd
KO:010400
|
Korea | ₩25.51 Billion |
|
Dev Information Technology Limited
NSE:DEVIT
|
India | Rs782.38 Million |
|
SHINWON CONSTRUCTION COMPANY Ltd
KQ:017000
|
Korea | ₩109.22 Billion |
|
Primega Group Holdings Limited Ordinary Shares
NASDAQ:PGHL
|
USA | $9.08 Million |
|
Marker Therapeutics Inc
NASDAQ:MRKR
|
USA | $3.35 Million |
|
Asia Poly Holdings Bhd
KLSE:0105
|
Malaysia | RM77.39 Million |
|
Dubber Corporation Ltd
AU:DUB
|
Australia | AU$23.21 Million |
|
Samyang Holdings Corp
KO:000075
|
Korea | ₩2.29 Trillion |
Liability Composition Analysis (2020–2024)
This chart breaks down Defence Therapeutics Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see DTC stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.08 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.89 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Defence Therapeutics Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Defence Therapeutics Inc. (2020–2024)
The table below shows the annual total liabilities of Defence Therapeutics Inc. from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-06-30 | €4.06 Million ≈ $4.75 Million |
+106.55% |
| 2023-06-30 | €1.97 Million ≈ $2.30 Million |
+77.61% |
| 2022-06-30 | €1.11 Million ≈ $1.29 Million |
+805.66% |
| 2021-06-30 | €122.26K ≈ $142.93K |
+152.85% |
| 2020-06-30 | €48.35K ≈ $56.53K |
-- |
About Defence Therapeutics Inc.
Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting vario… Read more